Coronavirus weekend news – Chinese media, Global Times, reports via Twitter that an official at the country’s National Health Commission:
says China has officially launched emergency use of a vaccine
the vaccine has been in clinical trial since July 22
GT also report on a more than 20,000 person phase III clinical trial in the UAE of Sinopharm’s COVID19 vaccine
has shown a high level of safety
efficacy is currently under observation
Both of the GT items are tweets only, not accompanied by further articles for more information.
There is one more that is accompanied by an article – saying that China’s first recombinant protein COVID-19 vaccine made from insect cells has been approved for clinical trials by the National Medical Products Administration.
vaccine is being developed by the State Key Laboratory of Biological Therapy of Sichuan University affiliated West China Hospital
vaccine uses insect cells to multiply in the culture medium and introduces the gene of COVID-19 into insect cells, which means the cell can be used as a factory to produce high-quality recombinant vaccine proteins and purify them for refinement.
vaccine was tested on monkeys and other animals, and was found to have a good protective effect against COVID-19 infection, with no obvious side effects
Given the history of how markets view vaccine news (generally positively) this threefer from the GT might be a boost for sentiment on Monday. There is still plenty of time left over the weekend for less than favourable stories to develop, stay tuned.
The US FDA authorised the emergency use of a new saliva based laboratory diagnostic test for coronavirus.
A key difference is the speed of the test, its being described as a ‘game changer’.
The sped allows more people to access rapid easily.
Stephen Hahn, the Food and Drugs Administration Commissioner:
“Providing this type of flexibility for processing saliva samples to test for COVID-19 infection is groundbreaking in terms of efficiency and avoiding shortages of crucial test components like reagents”
Its called SalivaDirect
has been tested amongst US National Basketball Association (NBA) players and staff
simpler, less expensive, less invasive than nasopharyngeal (NP) swabbing
yields similar outcomes as NP swabbing
ps. For clarity, this is a test for the infection, not a treatment. That is clear above, but wanted to restate it.
That brings the total confirmed cases in the country to nearly 2.4 million
India is among the countries that have been hit the hardest by the pandemic as the struggle to balance between the health crisis and the economic fallout is particularly stark.
As for the health crisis, the bright side is that over 1.6 million of those infected has recovered from the disease. However, the spread is still outpacing the number of recoveries:
At the start of July, India reported ~220,000 active cases in the country. That figure is now ~643,000. The only positive – if you really want to look at it that way – is that the mortality sits at just ~1.9%. That is better than the ~3.2% seen in Brazil and the US.
In the bigger picture, as long as the health crisis worsens in India, it will have an impact on the global economic situation in general. Before the pandemic, there have been talks that India’s share of global growth might rival that of US, China in the next decade.
They were already among the top five – some would argue top three – contributors of global growth over the past few years, so any major setback to India will also be a setback for the global economy in that sense.